Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for ion channels.
Fig. 1. The sreening workflow of Receptor.AI
It features detailed molecular simulations of the ion channel in its native membrane environment across its open, closed, and inactivated forms, coupled with ensemble virtual screening considering conformational mobility in these states. Potential binding sites are explored within the pore, in the gating region, and at allosteric locations to encompass all potential mechanisms of action.
Key features that set our library apart include:
partner
Reaxense
upacc
P22459
UPID:
KCNA4_HUMAN
Alternative names:
HPCN2; Voltage-gated K(+) channel HuKII; Voltage-gated potassium channel HBK4; Voltage-gated potassium channel HK1; Voltage-gated potassium channel subunit Kv1.4
Alternative UPACC:
P22459
Background:
Potassium voltage-gated channel subfamily A member 4 (Kv1.4) is a critical component in the regulation of potassium ion flow across cell membranes. This protein, encoded by the gene P22459, forms both homotetrameric and heterotetrameric channels, influencing cellular excitability. The dynamic nature of Kv1.4, alternating between open and closed states in response to voltage changes, underpins its pivotal role in neuronal signaling and muscle contraction.
Therapeutic significance:
Kv1.4's involvement in Microcephaly, cataracts, impaired intellectual development, and dystonia with abnormal striatum highlights its potential as a therapeutic target. Understanding the role of Kv1.4 could open doors to potential therapeutic strategies for treating neurological disorders characterized by cognitive impairment and motor dysfunction.